ISO SARS-CoV-2 Antigen Influenza AB Test Kit Professional

Rapid Test Kit SARS-CoV-2 Antigen & Influenza A/B Rapid Test Kit

Intended Use

This rapid test provides a simple, rapid detection as an aid in the differential diagnosis of SARS-CoV-2 Antigen and Influenza A&B using nasal swab specimens. This easy- to- use product and rapid results can be used for the screening of early infected patients and asymptomatic patients. It is also effective supplement for nucleic acid detection.

Specification

Main Components

• 20 Test cassettes
• 20 Sample extraction
• 20 Sample tubes
• 20 Swabs
• 1 Instruction Manual

Feature

• High Accuracy, Specificity and Sensitivity
• Detection of mutation 
• Safety and Reliabkle
• Simple Operation without Extra Instrument
• Results in 15 minutes and easy to read

Use  Step

• Take out the test cassette from the sealed pouch, place it on a clean and level surface with the sample port well up.

• Apply 2 full drops of the treated sample (60μl-70μl) vertically into each of the two sample wells of the test cassette.

• Observe the test results immediately within 15~20 minutes, the result is invalid over 20 minutes.

Interpretation Of Result

• POSITIVE: The presence of T (T on nCoV /A or B on Flu) and C lines within the reaction window indicate a positive result on SARS-CoV-2 or Flu A and/or B infection or co-infection.

• NEGATIVE: One colored line appears in the control region(C). No apparent colored line appears in the test region (T on nCoV /A or B on Flu). The negative result does not indicate the absence of analytes in the sample, it only indicates the level of tested analytes in the sample is less than the minimum detection limit

• INVALID: No colored lines appear, or control line fails to appear, indicating that the operator error or reagent failure. Verify the test procedure and repeat the test with a new testing device.

Applications

• Clinical department, Emergency department, Fever department
• Disease control center
• Primary screening of Inluenza A/B virus
• Risk assessment of Influenza A/B virus
• High susceptible population and infant screening